HTuO Biosciences, a biotech company specializing in molecular simulation for drug discovery, has recently joined Johnson & Johnson Innovation - JLABS as a resident virtual company.

The company aims to transform drug design and optimization with its platform, AtomForge, which utilizes a proprietary physics engine and machine learning. AtomForge is expected to revolutionize molecular modeling, drug discovery, and approaches to targeting undruggable proteins.

Dr. Anthony Fejes, CEO and co-founder of HTuO Biosciences, expressed enthusiasm for the collaboration:

"We're excited to be part of JLABS. It will provide valuable mentorship, industry connections, and research capabilities. This opportunity underscores the strength of our technology, team, and the biotech sector in British Columbia."

HTuO Biosciences is now a virtual company within Johnson & Johnson Innovation - JLABS, a global network supporting innovators in delivering health and wellness solutions worldwide. JLABS assists pharmaceutical, medical technology, and health tech entrepreneurs in bringing their solutions to market.

 

Source: businesswire.com

Report Abuse